Surgical Innovations Group

SUN · AIM · Health Care · mcap £3.7m · 0.4p 1 open situation →

EV: £4.0m
EV / EBIT: –
Net debt: £309k
FCF yield: 13.1%
Revenue: £11.5m
Share price 1y: −30%
Insiders 12m: no deals
Next report: around 20 Apr

Beta Briefing, track record and signals & risks are not ready for Surgical Innovations Group yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Strategic review for shareholder value Profit warning

Open · 1

Sale process / strategic review

Strategic review for shareholder value

Review ongoing; CEO change announced

The Board began a strategic review in April 2026 to optimise shareholder value, with no outcome or timetable given. This announcement changes the CEO: David Marsh moves to non-executive and Alex Warnock takes over on 1 October 2026. The review is not mentioned.

New CEO: Alex Warnock, ex-Group Managing Director of SDI Group plc, joins as CEO on 1 October 2026
Outgoing CEO: David Marsh becomes Non-Executive Director on 1 October 2026 and supports the new CEO
Board view: Chairman says Warnock has the right skillset to execute future plans and deliver long term value
Review status: Not mentioned in this announcement; no outcome or timetable

28 Sep 2026 Review ongoing; CEO change announced
21 Apr 2026 Board reviewing options

Open the full view – chart and every step →

Closed · 1

Upgrade / downgrade cycleProfit warning profit warning · 18 Dec 2025 – 18 Mar 2026 −14%

Company filings. Not investment advice.